(NYSE: TMO) Thermo Fisher Scientific's forecast annual revenue growth rate of 4.56% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 6.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.64%.
Thermo Fisher Scientific's revenue in 2026 is $47,351,000,000.On average, 31 Wall Street analysts forecast TMO's revenue for 2026 to be $17,965,943,923,452, with the lowest TMO revenue forecast at $17,374,971,113,992, and the highest TMO revenue forecast at $18,761,070,976,180. On average, 31 Wall Street analysts forecast TMO's revenue for 2027 to be $18,922,986,410,496, with the lowest TMO revenue forecast at $18,168,245,587,380, and the highest TMO revenue forecast at $20,026,382,665,400.
In 2028, TMO is forecast to generate $20,100,115,323,132 in revenue, with the lowest revenue forecast at $19,226,438,906,388 and the highest revenue forecast at $21,587,366,017,284.